Viking Therapeutics' Q3 Catalyst That Could Turn Eli Lilly's and Novo Nordisk's Daily Weight Loss Pill Strategy Upside Down
2/6 17:08
Key PointsVK2735 is being developed in both subcutaneous and oral forms, and upcoming Phase 1 maintenance trial results are a major catalyst....